Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

Summary

This is a 12-week study for the treatment of chronic persistent symptoms in participants with schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics who fulfill the screening criteria will be randomized to receive either an FDA-approved drug or placebo in addition to the current treatment. Safety will be closely monitored through vital signs, various tests, and blood and urine samples.

Timeline

Start

2004-05

Primary completion

2005-07

Completion

2005-07

Drugs

Indications